Listing analysis and research matching GlaxoSmithKline:
Tykerb's implications for partnerships
On March 13 2007 GlaxoSmithKline's cancer drug Tykerb (lapatinib ditosylate) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer. Targeted to patients who carry the HER2 gene, the approval opens up partnership opportunities in the field of diagnosis and pharmacogenomics.
Biopharmaceutical partnering in China
Multinational pharmaceutical companies are increasingly investing in China through alliances and the building of new centres. Much of the investment is to supplement rather than replace the research and development already occurring outside China and is focused on development and processes than be easily codified and regulated.
